GSK Bio
NEWS
Sanofi and GlaxoSmithKline reported that their potential COVID-19 booster shot delivered good immune response in its preliminary clinical trials.
There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
Despite having 37 new mutations in the viral spike protein, there does not appear to be any deaths associated with Omicron, although it’s spreading rapidly in South Africa.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
GlaxoSmithKline said early research shows its monoclonal antibody is demonstrating efficacy against the newest strain of COVID-19.
23andMe raised $592 million in proceeds from the IPO and, as of September 30, had about $700 million. With that cash in hand, it plans to push faster and deeper into drug development.
Genoskin’s solution is to develop the technologies to replace animals and humans in clinical studies with virtual models, steadily pushing living creatures further and further from testing.
Pfizer veteran Phil Dormitzer will assume the role of Global Head of Vaccines beginning Friday.
Are you looking for doctor careers in the pharma sector? Here is everything you need to know about how you can choose a reputable and growing pharma career.
JOBS
IN THE PRESS